Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aprameya EngineeringNSE:APRAMEYA +0.31%41 EV-to-EBITDA is 25.85 as of Aug. 07, 2026, which is 5% above its 10-year median of 24.57. GuruFocus rates NSE:APRAMEYA with a GF Score™ of 41/100. The stock has 6 warning signs investors should review. Among 512 Medical Devices & Instruments companies, Aprameya Engineering ranks worse than 74.22% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Aprameya Engineering's enterprise value is ₹2,849.8 Mil.
Aprameya Engineering's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was ₹110.2 Mil. Therefore, Aprameya Engineering's EV-to-EBITDA for today is 25.85.
The historical rank and industry rank for Aprameya Engineering's EV-to-EBITDA or its related term are showing as below:
NSE:APRAMEYA'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.96 Med: 24.57 Max: 43.64
Current: 25.85
During the past 7 years, the highest EV-to-EBITDA of Aprameya Engineering was 43.64. The lowest was 7.96. And the median was 24.57.
NSE:APRAMEYA's EV-to-EBITDA is ranked worse than 74.22% of 512
companies
in the Medical Devices & Instruments industry
Industry Median: 14.645
vs NSE:APRAMEYA: 25.85
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Aprameya Engineering's PE Ratio (TTM) for today is calculated as:
Aprameya Engineering's share price for today is ₹146.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Aprameya Engineering's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹2.680.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Aprameya Engineering's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:APRAMEYA vs ISRG, BDX, MDLN: EV-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Aprameya Engineering's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aprameya Engineering EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Aprameya Engineering's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Aprameya Engineering's EV-to-EBITDA falls into.
Aprameya Engineering's current Enterprise Value is ₹2,849.8 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Aprameya Engineering's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was ₹110.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aprameya Engineering (NSE:APRAMEYA) has a EV-to-EBITDA of 25.85 as of Aug. 07, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Aprameya Engineering. This is near median its historical median of 24.57. Over the past decade, Aprameya Engineering's EV-to-EBITDA has ranged from 7.96 to 43.64. According to the industry distribution chart, Aprameya Engineering ranks #380 out of 512 companies in the Medical Devices & Instruments industry, placing it in the top 74.2%.
Is Aprameya Engineering's EV-to-EBITDA too high?
Aprameya Engineering's current EV-to-EBITDA of 25.85 is near median its 10-year median of 24.57. Over the past 10 years, this metric has ranged from a low of 7.96 to a high of 43.64. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.65. Aprameya Engineering's value of 25.85 is 76.5% above this industry median. Based on the distribution chart, Aprameya Engineering ranks #380 out of 512 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Aprameya Engineering has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does Aprameya Engineering's EV-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Aprameya Engineering ranks #380 out of 512 companies for EV-to-EBITDA. This places Aprameya Engineering in the lower half of its industry. The industry median EV-to-EBITDA is 14.65. Aprameya Engineering's value of 25.85 is 76.5% above this benchmark. Historically, Aprameya Engineering's own EV-to-EBITDA has ranged from 7.96 to 43.64 over the past decade. While the company's 10-year median is 24.57 vs. the industry median of 14.65, Aprameya Engineering has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.65, based on 512 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aprameya Engineering's current EV-to-EBITDA of 25.85 is 76.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Aprameya Engineering. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aprameya Engineering's current EV-to-EBITDA is 25.85, which is near median its own 10-year median of 24.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aprameya Engineering stock overvalued right now?
Aprameya Engineering (NSE:APRAMEYA) has a current EV-to-EBITDA of 25.85. The current EV-to-EBITDA is 25.85, which is near median its 10-year median of 24.57 and 76.5% above the Medical Devices & Instruments industry median of 14.65. Aprameya Engineering's overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Aprameya Engineering (NSE:APRAMEYA), the current EV-to-EBITDA is 25.85 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aprameya Engineering Ltd is engaged in the business of installation, set up & maintenance of Intensive Care Units (ICU), Neonatal Intensive Care Units (NICU), Pediatric Intensive Care Units (PICU), Operation Theatre, dialysis centres and prefabricated structure ward (hereinafter referred to as Healthcare Infrastructure projects) in the hospitals and medical care centers on turnkey basis with the supply of high-value healthcare equipment and diagnostic equipment to private hospitals, Government hospitals, and medical practitioners. The company has two Business segments: Trading of Medical support Equipment (Trading Sales) and Supplies for Infra Projects for health care sectors (Turnkey project supplies). Key revenue is generated from Trunkey Project Supply.
41GF Score
Get the complete analysis for NSE:APRAMEYA
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:APRAMEYA has been successfully added to your 
